Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Non-Current Deffered Revenue (2019 - 2025)

Vivos Therapeutics' Non-Current Deffered Revenue history spans 7 years, with the latest figure at $1000.0 for Q3 2025.

  • Quarterly results put Non-Current Deffered Revenue at $1000.0 for Q3 2025, down 99.44% from a year ago — trailing twelve months through Sep 2025 was $1000.0 (down 99.44% YoY), and the annual figure for FY2024 was $97000.0, down 66.44%.
  • Non-Current Deffered Revenue for Q3 2025 was $1000.0 at Vivos Therapeutics, down from $5000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $533000.0 in Q1 2024 to a low of $1000.0 in Q3 2025.
  • The 5-year median for Non-Current Deffered Revenue is $250000.0 (2023), against an average of $236235.3.
  • The sharpest move saw Non-Current Deffered Revenue skyrocketed 158.04% in 2023, then plummeted 99.44% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $343000.0 in 2021, then tumbled by 67.35% to $112000.0 in 2022, then skyrocketed by 158.04% to $289000.0 in 2023, then crashed by 66.44% to $97000.0 in 2024, then plummeted by 98.97% to $1000.0 in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $1000.0, $5000.0, and $22000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.